Peru Tecnovigilance under R.M. N° 539-2016/MINSA: Registration Holder Obligations

Regulatory information verified as of October 29, 2026

1. Key takeaways

Obtaining a Peruvian health registration certificate (Certificado de Registro Sanitario, CRS) does not close the compliance loop: before the first batch of products is placed on the market, the registration holder (Titular del Registro Sanitario, PRH) must have four elements in place simultaneously — a tecnovigilance system, a local responsible person, documentation, and reporting procedures. Failing that, any product already in circulation sits in a state of missing obligations. The legal foundation of this entire set of duties is the Norma Sanitaria que Regula las Actividades de Farmacovigilancia y Tecnovigilancia de Productos Farmacéuticos, Dispositivos Médicos y Productos para la Salud, namely R.M. N° 539-2016/MINSA, published on 2016-07-27. In project reviews we repeatedly encounter the same pattern: manufacturers assume that vigilance is something done only after an incident occurs, and then cannot produce even the appointment letter of the responsible person or a document inventory. Regulatory information verified as of October 29, 2026.

2. Legal basis

Secondary sources also record that D.S. N° 013-2014-SA requires the filing of a Responsable de Tecnovigilancia (vigilance responsible person) with the competent authority; we have not yet obtained the original text of that reference number in El Peruano or its specific article numbers. Accordingly, the statutory duties of the vigilance responsible person are cited from R.M. N° 539-2016/MINSA as a priority, and this item is marked as pending verification.

3. Expert insights

Insight 1 | Responsibility for vigilance is dual-track — holder plus establishment, not one-sided

R.M. N° 539-2016/MINSA places duties on two lines: the registration holder as the product-responsibility entity, and the pharmaceutical establishments that actually conduct activities (including wholesale distributors, Droguería, and laboratories, Laboratorio). The mechanical implication is that even where an offshore manufacturer has appointed a local PRH, the vigilance duties cannot be fully carved out by contract — the enforcement authority faces the domestic entities, and the PRH will in turn seek recovery from the manufacturer. In contract reviews we insist on drafting vigilance responsibilities, information-transfer deadlines and cost allocation into enforceable annex clauses, rather than a single line stating that vigilance is the buyer’s responsibility.

Insight 2 | The demonstrability of the system matters more than the system text itself

The regulation requires establishing a vigilance system and appointing a local responsible person, while maintaining training records and documentation. The real review logic is evidence-driven: does the appointment letter name a specific individual and a substitute; does training cover frontline distributor personnel; can the complaint ledger be traced back to batch numbers and user facilities. A system written in a manual but with no trace of execution counts as no system during an inspection. That is why we require clients to file vigilance documents in six segments — appointment, training, collection, assessment, reporting and review — rather than piling up training sign-in sheets.

Insight 3 | GTP and post-market studies: do not schedule against unadopted provisions

The final guideline on Good Tecnovigilance Practices (Buenas Prácticas de Tecnovigilancia, GTP) has not yet been finalized. Secondary sources likewise record that R.M. N° 734-2024/MINSA, the new Peruvian medical device regulation, remains in public consultation, and its final reference number and effective date are subject to the official publication. For matters described as required submissions, such as risk management plans and post-market studies, we therefore build the skeleton first under the principled requirements of the Category A regulation R.M. N° 539-2016/MINSA, leaving interfaces for specific formats and trigger conditions. All GTP-related details are marked as subject to the official publication of DIGEMID and MINSA, and no client should be promised a specific submission milestone based on rumored versions.

4. Practical recommendations

1. Complete the appointment of the vigilance responsible person before the first shipment; the document must state the name, contact details, delegated authority and a designated substitute, and the single reporting channel must be communicated in writing across the entire distribution chain.
2. Establish a standard operating procedure (SOP) for classifying complaints versus suspected adverse events, and place the two deadlines — 24 hours for serious events and 20 calendar days for moderate and mild events — on the front page of the SOP.
3. Build a document inventory in six segments — appointment, training, ledger, assessment, reporting, review — with a single accountable filing owner, so that every incoming piece of information can be traced back to a batch number.
4. Subscribe to the safety alerts of the competent authorities of the country of origin and of countries with high sanitary vigilance such as the European Union and the United States (Países de Alta Vigilancia Sanitaria), and establish a written process for converting foreign alerts into local assessments.
5. Agree in the contracts with the PRH and distributors on deadlines for returning vigilance information, and list delayed information return leading to overdue reports as an accountable breach.

5. Verification checklist

□ The name of the registration holder (PRH) for this product has been checked item by item against the duty list under R.M. N° 539-2016/MINSA (regulatory information verified as of October 29, 2026).

□ The appointment letter of the local vigilance responsible person has been confirmed to include a substitute and to cover all distribution tiers.

□ A training ledger exists, and the most recent training session included frontline distributor personnel.

□ An SOP for classifying and reporting suspected adverse events has been written, containing the two deadlines of 24 hours and 20 calendar days.

□ The list of sources for monitoring safety alerts from other countries and the person accountable for local assessment have been defined.

□ The periodic safety report cadence has been confirmed: every 6 months for the first 2 years, annually for the following 3 years, and every 5 years from year 6 (specific article numbers pending verification; the official publication prevails).

□ The status of the GTP details has been confirmed: the final guideline has not been adopted, and all related items are marked as subject to the official publication of DIGEMID and MINSA.

Regulatory information verified as of October 29, 2026.

GRZAN provides medical device registration and post-market compliance support in Peru for manufacturers, importers and authorized representatives. For assistance, contact info@grzanglobal.com.